Cooperating in Advanced MRI Technology for Diagnosis and Treatment Planning of Brain Disorders
ELM GROVE, WI / ACCESSWIRE / August 20, 2024 / Prism Clinical Imaging, Inc. (Prism), experts in brain mapping software and applications, and Sora Neuroscience, Inc. (Sora), a brain imaging technology company, today announced a letter of cooperation to assist one another in performing validation testing and commercialization of products for brain resting state functional MRI (rs-fMRI) analysis.
Sora Neuroscience is licensee of a portfolio of resting state network mapping technology developed and clinically investigated at Washington University in St. Louis (WashU) over the past decade. These machine learning algorithms have been trained for brain tumor and epilepsy patient surgery planning. Prism provides clinical software and web-based services for acquisition, analysis, display, and export of functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), and other data. It also provides tools to combine fMRI and DTI with other imaging such as PET.
These technologies identify critical spatial relationships and functional structures to avoid during treatment, such as surgery.
About Prism Clinical Imaging
Prism Clinical Imaging, Inc., provides clinicians with imaging tools to diagnose and plan treatment for brain disorders including tumors, epilepsy, and other neurological disorders. Deployment options range from on-premises to cloud-based. Please visit www.prismclinical.com for further information. Follow Prism on LinkedIn and Twitter, @PrismClinical.
Contact: James L. Reuss, PhD (CEO), jreuss@prismclinical.com
About Sora Neuroscience, Inc.
Sora Neuroscience, Inc. is a brain imaging technology company committed to providing clinically useful and rigorously tested resting state functional MRI analysis tools ready to be integrated into existing clinical workflows. Sora was founded by leading resting state fMRI innovators at Washington University in St. Louis (WashU) and is headquartered in Minneapolis, Minnesota. For more information, please visit www.soraneuroscience.com.
Contact: Stephen R. Schaefer, JD (CEO), steve@soraneuroscience.com
SOURCE: Prism Clinical Imaging, Inc.
View the original press release on accesswire.com
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…
The New Year Introduces Continuum's Entry-Level Tier, Starting at $25,000 Per YearNEW YORK, Dec. 22,…
BOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with…
CHICAGO, Dec. 22, 2025 /PRNewswire/ -- TrustCommerce®, a Sphere company and leading provider of end-to-end…
MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is…
Andreessen Horowitz leads the funding round which will accelerate the company's leadingtelehealth marketplaceAUSTIN, Texas, Dec.…